Tracking Compounded Semaglutide & Tirzepatide Doses

Tracking compounded semaglutide or tirzepatide means keeping an organized record of your vials and doses: each vial's concentration, your dose in both units and milligrams, the date you started drawing from it, and its beyond-use date. The goal is purely logistical, to prevent two specific problems, dosing confusion between vials of different strengths and running out unexpectedly. This is a guide to logging and organization, not a dosing protocol, and every dose decision belongs to your prescriber and pharmacist.

One important note up front on regulatory status, because it has shifted. Broad compounding of semaglutide and tirzepatide was permitted largely because the FDA had declared shortages of the branded products. As of 2026, after the FDA resolved those shortages and wound down its enforcement discretion, broad compounding of these GLP-1 medications is largely no longer permitted, though some limited contexts may persist. This is an evolving area, so confirm your current situation with your prescriber and pharmacist rather than relying on any single article.

Why compounded GLP-1 tracking is its own thing

A branded pen like Ozempic/Wegovy (semaglutide) or Mounjaro/Zepbound (tirzepatide) does the math for you: you dial a dose and the device delivers it. Compounded GLP-1s have historically worked differently. They are typically supplied in multi-dose vials, and the dose is drawn manually with an insulin syringe measured in units. That hands-on step is exactly where tracking earns its keep.

The core challenge is that a "unit" is a volume measurement, not a dose of medication. How many milligrams of drug sit in a given number of units depends entirely on the vial's concentration, which is the amount of drug per milliliter of liquid. Concentration, the mg per mL printed on your vial, is the hinge the whole calculation turns on.

Compounders have historically supplied vials at varying concentrations: semaglutide commonly around 2.5 or 5 mg/mL and tirzepatide around 17 or 20 mg/mL, though it varied by pharmacy. That variation is the heart of the problem. The same number of units drawn from two differently concentrated vials delivers two different doses, and concentration confusion has been documented as a source of dosing errors in FDA adverse-event reports. Accurate per-vial records are how you keep that straight.

The numbers to keep straight: concentration, units, and mg

Below is a reference table showing how concentration, an injection volume, and a resulting milligram amount relate, plus what to log per vial. Read this as an illustration of the relationships, not as instructions for what to draw. Your actual dose, in both units and mg, is set by your prescriber, and the exact conversion for your vial should be confirmed with your prescriber or pharmacist against your specific label.

If concentration is	Then 1 insulin unit (0.01 mL) holds	And your logged dose in mg is	What to log per vial
2.5 mg/mL	0.025 mg	(units drawn) x 0.025 mg	Concentration, total mg/volume, start date, beyond-use date, storage
5 mg/mL	0.05 mg	(units drawn) x 0.05 mg	Concentration, total mg/volume, start date, beyond-use date, storage
17 mg/mL	0.17 mg	(units drawn) x 0.17 mg	Concentration, total mg/volume, start date, beyond-use date, storage
20 mg/mL	0.20 mg	(units drawn) x 0.20 mg	Concentration, total mg/volume, start date, beyond-use date, storage

Note: a standard U-100 insulin syringe defines 1 unit as 0.01 mL, which is the basis for the middle column. Always verify against your own label and your pharmacist's instructions.

The reason to log both units and milligrams is that they serve different purposes. Units are what you physically draw; milligrams are how doses are described in studies, on branded products, and in conversations with your prescriber. Keeping both means you can speak either language without re-deriving the conversion under pressure, which is when mistakes happen.

Beyond-use date: the field people forget

A beyond-use date, or BUD, is the date after which a compounded preparation should no longer be used, assigned by the pharmacy. It is not the same as a manufacturer's expiration date, and it is usually shorter. The BUD accounts for the realities of a compounded multi-dose vial, including potency loss over time and contamination risk once the vial has been entered repeatedly.

Tracking the BUD matters for safety, not just inventory. Using a vial past its BUD risks reduced potency or contamination, which is why your pharmacy assigns it and why your log should carry it. Pair the BUD with the start date and your dosing frequency and you can also see your runout point coming, so a refill conversation happens before you are caught short. Storage instructions belong in the same record, since compounded products often have specific refrigeration requirements.

A simple per-vial logging routine

You do not need a spreadsheet with twenty columns. A workable routine captures the vial once and each dose as it happens.

When a new vial arrives, log it once:

• Concentration in mg per mL, copied exactly from the label.
• Total amount, as total mg or total volume, so you can track what remains.
• The date you first draw from it.
• The beyond-use date.
• Storage instructions (for example, refrigeration).

Then for every injection, log:

• The date, and the day of week so your weekly cadence stays visible.
• The dose in units, as drawn.
• The equivalent in mg, using your confirmed conversion.
• The injection site, which ties into good site rotation and schedule tracking.
• Anything notable to mention to your prescriber.

That habit does three things at once. It keeps a running tally of how much vial is left, it prevents the "wait, which vial am I on" confusion when concentrations differ, and it builds a clean dose timeline that the rest of your data can hang on. As with any GLP-1, that timeline is what lets you make sense of how appetite and side effects move across your week, which is the whole idea behind the dose week and PK curve.

What tracking does and does not do

Be clear-eyed about the boundary. A tracker organizes information; it does not make clinical decisions. It will not tell you what dose to take, when to titrate, or whether a vial is safe to use. Those are questions for your prescriber and pharmacist, full stop. What a good log does is make sure that when you act on their instructions, you act on accurate, well-organized numbers rather than memory and guesswork.

The two failure modes it guards against are worth naming again. The first is dosing confusion, especially the concentration mix-up that turns the same number of units into a different milligram dose, a documented source of real-world errors. The second is running out without warning, which a BUD-and-runout view prevents by surfacing the refill point in advance. Both are logistics problems, and logistics problems respond well to a system.

The mix-ups a log is meant to catch

It helps to know what kind of errors organized tracking is designed to prevent, because they are usually mundane rather than dramatic. The most common is switching to a new vial at a different concentration and continuing to draw the same number of units out of habit, which silently changes the milligram dose. A log that carries each vial's concentration as its own field makes that switch visible instead of automatic.

A second is losing the thread on which vial is open and how much is left, which is how people end up either wasting medication or discovering an empty vial on dosing day. A running tally that deducts each draw keeps the remaining amount honest. A third is letting a vial drift past its beyond-use date unnoticed, which a dated record and a reminder are well suited to prevent.

None of these are exotic. They are the ordinary friction of managing a multi-dose vial by hand, and they are exactly the kind of thing a checklist beats memory at. The value of tracking is not that it makes you smarter; it is that it removes the moments where a small lapse becomes a dosing error.

Myo supports compounded dosing in both units and mg, and its supply and vial tracker stores concentration, beyond-use date, auto-deducts each logged dose, and sends runout alerts, so your vial log lives in the same place as the muscle and protein data that tells you the protocol is actually working. That last part is the point of doing any of this: the dose is only worth tracking because of what you are trying to achieve with it, which for many people is losing fat while holding onto muscle. For how the tracking choices compare across apps, see our GLP-1 tracking apps comparison, and for the bigger muscle picture, the complete guide to GLP-1 and muscle loss.

Whatever tool you use, the principle holds: track the vial, track the dose in both units and mg, watch the beyond-use date, and defer every clinical decision to the people qualified to make it.

References

• UIC Drug Information Group, dig.pharmacy.uic.edu (compounded semaglutide/tirzepatide context and unit-to-mg considerations).
• Pharmacy Times (FDA resolution of GLP-1 shortages and wind-down of compounding enforcement discretion, 2025 to 2026).
• Elite Health Center, on compounded medication beyond-use dating and storage.
• FDA adverse-event reporting on dosing errors associated with compounded GLP-1 concentration confusion.
• Your prescriber and compounding pharmacist remain the authority for dosing, conversions, storage, and the current regulatory status of any compounded product.